WuXi Biologics announced its interim results, with net profit attributable to shareholders of approximately RMB 2.339 billion, a year-on-year increase of 56%

According to the Zhitong Finance APP, WuXi Biologics (02269) announced its mid-year results for 2025, with revenue of approximately RMB 9.953 billion, a year-on-year increase of 16.1%; gross profit of approximately RMB 4.253 billion, a year-on-year increase of 27%; net profit attributable to shareholders of the company of approximately RMB 2.339 billion, a year-on-year increase of 56%; adjusted net profit attributable to shareholders of the company of approximately RMB 2.389 billion, a year-on-year increase of 6.2%; basic earnings per share of RMB 0.58.

The announcement stated that the revenue growth was mainly attributed to (i) the successful execution of the "Follow and Win Molecules" strategy, along with a leading technology platform, industry-best project delivery times, and an excellent track record of project execution, driving the group's revenue growth; (ii) the expansion of the group's service offerings in the biopharmaceutical industry, including research discovery, pre-IND development, and clinical and commercial production, based on rapidly developing technology platforms such as ADC (antibody-drug conjugates) and bispecific antibodies; (iii) revenue growth from research services generated by multiple advanced technologies of the group; and (iv) the group's utilization of existing and new production capacity, including the ramp-up of capacity at its European production base.

In the first half of 2025, the group set a record for the number of new integrated projects. During the reporting period, the group added 86 integrated projects, bringing the total to 864. As of June 30, 2025, the number of the group's preclinical projects and early clinical projects increased to 429 and 344, respectively, demonstrating the group's sustainable development capabilities. The group's late-stage clinical and commercial production businesses also showed steady growth, with project numbers reaching 67 and 24, respectively, as of June 30, 2025. Additionally, by executing the "Win Molecules" strategy, the group successfully secured 9 external projects during the reporting period, including 2 late-stage clinical projects, further unleashing growth momentum.

The total amount of uncompleted orders for the group increased to USD 20.3 billion as of June 30, 2025, including uncompleted service orders of USD 11.4 billion and uncompleted potential milestone payment orders of USD 9 billion. Meanwhile, the total amount of uncompleted orders over three years increased to USD 4.2 billion as of June 30, 2025. The timing and probability of revenue recognition for potential milestone payment orders may vary, as they are subject to factors such as project success rates and project progress, which the group may not be able to fully control